Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 May 10;79(18):1802-1813.
doi: 10.1016/j.jacc.2022.02.048.

High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S

Adam J Nelson  1 , Kevin Haynes  2 , Sonali Shambhu  2 , Zubin Eapen  3 , Mark J Cziraky  2 , Michael G Nanna  4 , Sara B Calvert  5 , Kerrin Gallagher  2 , Neha J Pagidipati  1 , Christopher B Granger  6
Affiliations

High-Intensity Statin Use Among Patients With Atherosclerosis in the U.S

Adam J Nelson et al. J Am Coll Cardiol. .

Abstract

Background: Preventive therapy among patients with established atherosclerotic cardiovascular disease (ASCVD) is generally underused. Whether new guideline recommendations and a focus on implementation have improved the use of high-intensity statins is unknown.

Objectives: This study sought to evaluate the patterns and predictors of statin use among patients with ASCVD.

Methods: In this retrospective cohort study, pharmacy and medical claims data from a commercial health plan were queried for patients with established ASCVD between January 31, 2018, and January 31, 2019. Statin use on an index date of January 31, 2019, was evaluated, as was 12-month adherence and discontinuation. Multivariable logistic regression was used to determine independent associations with statin use of varying intensities.

Results: Of the 601,934 patients with established ASCVD, 41.7% were female, and the mean age was 67.5 ± 13.3 years. Overall, 22.5% of the cohort were on a high-intensity statin, 27.6% were on a low- or moderate-intensity statin, and 49.9% were not on any statin. In multivariable analysis, younger patients, female patients, and those with higher Charlson comorbidity score were less likely to be prescribed any statin. Among statin users, female patients, older patients, and those with peripheral artery disease were less likely to be on a high-intensity formulation, whereas a cardiology encounter in the prior year increased the odds. The majority of high-intensity stain users achieved high levels of adherence.

Conclusions: Substantial underuse of statins persists in a large, insured, and contemporary cohort of patients with ASCVD from the United States. In particular, concerning gaps in appropriate statin use remain among younger patients, women, and those with noncoronary ASCVD.

Keywords: atherosclerosis; predictors; prevention; secondary prevention; statins.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr Nelson has received grants from Diabetes Australia and the Royal Australasian College of Physicians. Dr Haynes is an employee of HealthCore, a subsidiary of Anthem. Dr Shambhu is an employee of HealthCore, a subsidiary of Anthem. Dr Eapen is a previous employee of HealthCore. Dr Cziraky is an employee of HealthCore, a subsidiary of Anthem. Dr Nanna has received funding from the American College of Cardiology Foundation supported by the George F. and Ann Harris Bellows Foundation, and from the National Institute on Aging/National Institutes of Health from R03AG074067 (GEMSSTAR award). Dr Calvert is supported by U.S. Food and Drug Administration grant U18FD005292 and Clinical Trials Transformation Initiative membership fees. Dr Gallagher is an employee of HealthCore. Dr Pagidipati has received grants from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Novartis, Novo Nordisk, Regeneron, Sanofi, Verily Life Sciences; and has received consulting fees from Boehringer Ingelheim, Eli Lilly, AstraZeneca, and Novo Nordisk. Dr Granger has received research grants and consulting/speaker fees from Boehringer Ingelheim, Bristol Myers Squibb, Janssen Pharmaceutica Products, LP, and Pfizer; has received research grants from AKROS, Apple, AstraZeneca, Daichii-Sankyo, U.S. Food and Drug Administration, GlaxoSmithKline, Medtronic Foundation, and Novartis Pharmaceutical Company; and has received consulting/speaker fees from AbbVie, Bayer Corp US, Boston Scientific Corp, CeleCor Therapeutics, Correvio, Espero BioPharma, Medscape, Medtronic Inc, Merck, National Institutes of Health, Novo Nordisk, Rhoshan Pharmaceuticals, and Roche Diagnostics.

Figures

Figure 1.
Figure 1.. CONSORT Diagram.
Progressive identification of eligible participants based on inclusion criteria to generate final analytic cohort of 601 934.
Figure 2.
Figure 2.. Statin use among key subgroups.
Patients presented by baseline statin use (high-intensity = green; other statin = yellow, and no statin = orange) within key subgroups of age, gender and ASCVD phenotype. CAD - coronary artery disease; CeVD – cerebrovascular disease; PAD – peripheral artery disease;
Figure 3.
Figure 3.. Sankey diagram illustrating the dynamics of statin use in follow-up.
The proportion of patients receiving high-intensity statins are shaded green, those receiving non-high-intensity statins in yellow and no statin in orange. The black numbers represent the shaded proportion as a percentage of the overall population. The vertical lines represent 3-month intervals.
Central illustration.
Central illustration.. Statin use in 601934 ASCVD patients on 31st January 2019.
Proportion on high-intensity statin vs. other statin vs. no statin. Odds of high (vs. other) intensity statin use. Proportion of days covered among users of high-intensity statins.
See this image and copyright information in PMC

Comment in

References

    1. Lloyd-Jones DM, Leip EP, Larson MG et al. Prediction of lifetime risk for cardiovascular disease by risk factor burden at 50 years of age. Circulation 2006;113:791–8. - PubMed
    1. Lindh M, Banefelt J, Fox KM et al. Cardiovascular event rates in a high atherosclerotic cardiovascular disease risk population: estimates from Swedish population-based register data. Eur Heart J Qual Care Clin Outcomes 2019;5:225–232. - PMC - PubMed
    1. Collins R, Reith C, Emberson J et al. Interpretanttion of the evidence for the efficacy and safety of statin therapy. Lancet 2016;388:2532–2561. - PubMed
    1. Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350:1495–504. - PubMed
    1. LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 2005;352:1425–35. - PubMed

Publication types

Substances